Equine ACE2/hFc antibody and antigen (recombinant protein)
Diagnostic anti-Equine ACE2/hFc antibodies pairs and antigen for animal health (animal Equine/Horse acute respiratory distress syndrome) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Equine disease testing products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-EQU-ACE2/hFc-Ag01 | Equine ACE2/hFc | $3090.00 |
GMP-EQU-ACE2/hFc-Ab01 | Anti-Equine ACE2/hFc mouse monoclonal antibody (mAb) | $3090.00 |
GMP-EQU-ACE2/hFc-Ab02 | Anti-Equine ACE2/hFc mouse monoclonal antibody (mAb) | $3090.00 |
GMP-EQU-ACE2/hFc-Ab03 | Anti-Equine ACE2/hFc human monoclonal antibody (mAb) | $3090.00 |
GMP-EQU-ACE2/hFc-Ab04 | Anti-Equine ACE2/hFc human monoclonal antibody (mAb) | $3090.00 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. | GMP-EQU-ACE2/hFc-Ag01 |
Product Name | Equine ACE2/hFc |
Target/Biomarker | Equine ACE2/hFc |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Equine ACE2/hFc antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in ACE2/hFc level test of animal Equine/Horse with acute respiratory distress syndrome. |
Tag | His | Reconized/Reactive Specics | Equine ACE2/hFc |
Product description | Recombinant Equine ACE2/hFc protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-EQU-ACE2/hFc-Ab01,GMP-EQU-ACE2/hFc-Ab02 |
Target/Biomarker | Equine ACE2/hFc |
Product Name | Anti-Equine ACE2/hFc mouse monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Equine ACE2/hFc antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine ACE2/hFc antibodies in Equine ACE2/hFc level test of animal Equine/Horse with acute respiratory distress syndrome. |
Product description | Anti-Equine ACE2/hFc mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine ACE2/hFc antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-EQU-ACE2/hFc-Ab03,GMP-EQU-ACE2/hFc-Ab04 |
Target/Biomarker | Equine ACE2/hFc |
Product Name | Anti-Equine ACE2/hFc human monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Human lgG1 |
Bioactivity validation | Recombinant Equine ACE2/hFc antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine ACE2/hFc antibodies in Equine ACE2/hFc level test of animal Equine/Horse with acute respiratory distress syndrome. |
Product description | Anti-Equine ACE2/hFc mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker Information
Equine ACE2/hFc, a fusion protein positioned at the intersection of equine biology and molecular research, represents a milestone in scientific innovation. Comprising two distinct components - Equine ACE2 (Angiotensin-Converting Enzyme 2) and the human immunoglobulin Fc region (hFc) - it offers a multifaceted lens through which to explore the intricacies of equine cardiovascular physiology and its implications for zoonotic research.
At its core, Equine ACE2 is a pivotal player in the cardiovascular system of horses. As a membrane-bound metallopeptidase, it governs the conversion of Angiotensin II to Angiotensin 1-7, a transition that exerts potent control over blood pressure, fluid balance, and overall cardiovascular homeostasis in equines. Measuring Equine ACE2/hFc provides researchers with a privileged view into the molecular choreography that underpins equine cardiovascular health.
The fusion with the human immunoglobulin Fc region (hFc) is a stroke of molecular genius. It amplifies the versatility of Equine ACE2/hFc by enabling precise detection, purification, and manipulation in laboratory settings. This innovation empowers researchers to dissect the molecular intricacies governing equine ACE2 receptor biology with unparalleled precision, ushering in a new era of equine molecular research.
Beyond its utility in unraveling equine physiology, Equine ACE2/hFc assumes a central role in zoonotic research. With the increasing global focus on emerging infectious diseases, particularly exemplified by the COVID-19 pandemic, this fusion protein stands as a sentinel, guiding researchers as they explore the potential role of horses as reservoirs and vectors for zoonotic pathogens. It provides a unique platform to investigate interactions between equine ACE2 receptors and pathogens, offering insights into susceptibility, transmission dynamics, and the development of preventive strategies.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.